Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient completed a previous double-blind plecanatide study and was compliant with the study requirements.~* Patient is in good health without unstable acute illness or exacerbation of an unstable chronic illness or chronic disease that may affect study assessments, particularly if there has been a significant change to health status since the previous plecanatide study.~Exclusion Criteria:~* Patient has had major surgery including laparoscopic procedures requiring general anesthesia within 60 days of Day 1.~* Patient has a medical history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.~* Patient has taken a protocol-prohibited drug without the appropriate washout period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- Plecanatide 3.0 mg (Type: EXPERIMENTAL): Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
- Plecanatide 6.0 mg (Type: EXPERIMENTAL): Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).